Search - tctmd.com

Displaying 21 - 40 of 87

Sort: Relevancy | Date

News Daily News

CTO PCI Improves Total Myocardial Viability, PET Imaging Suggests

Yael L. Maxwell

December 13, 2021

News Conference News TCT 2021

FAME 3: PCI Fails to Demonstrate Noninferiority to Surgery in Three-Vessel CAD

Michael O'Riordan

November 04, 2021

News Daily News

New Chest Pain Guidelines Out at Last: Most Tests Have a Role

Michael O'Riordan

October 28, 2021

News Daily News

ORBITA Data Undercut the Idea PCI Does Best in Focal CAD

Caitlin E. Cox

August 06, 2021

News Conference News AHA 2020

When PCI Decisions Ignore FFR Results, Patients Pay a Price

Caitlin E. Cox

November 14, 2020

News Daily News

Swedish Data ‘Corroborate’ FFR’s Survival Benefit Seen in RCTs

Caitlin E. Cox

June 03, 2020

News Daily News

Functionally Significant Nonculprit Lesions Pose Risk in STEMI Patients

Michael O'Riordan

April 21, 2020

News Daily News

Diabetes Does Not Appear to Hinder FFR Insights for CAD

Caitlin E. Cox

January 09, 2020

News Daily News

CMR May Help Evaluate Nonculprit Lesions in STEMI Patients

Todd Neale

September 19, 2019

News Conference News EuroPCR 2019

Drug-Coated Balloons in STEMI ‘Safe and Feasible’ in Specific Circumstances: REVELATION

L.A. McKeown

May 22, 2019

News Conference News EuroPCR 2019

Off to EuroPCR 2019? Expect Mitral and Tricuspid Updates, Thin-Strut Stent Surprises, and ‘Strong’ Statements

Shelley Wood

May 16, 2019

Podcast TCTMD Talking Points

FAME 2: 3-Year Clinical and Cost-Effectiveness Outcomes of FFR-Guided PCI in Patients With Coronary Artery Disease

September 05, 2018

News Conference News ESC 2018

New ESC/EACTS Revascularization Guidelines Make Room for Radial First, STICH, and DES for All

Michael O'Riordan

August 29, 2018

News Daily News

ORBITA Redux: Lancet Correspondence Takes Talk of the Sham-Controlled PCI Trial to Further Heights

Michael O'Riordan

July 10, 2018

News Conference News EuroPCR 2018

Modest Benefit of PCI Over Medical Therapy in Patients With ‘Grey Zone’ FFR Lesions

Michael O'Riordan

May 23, 2018

Presentation EuroPCR 2018

Five-year Outcomes with PCI Guided by Fractional Flow Reserve in Patients with Stable Coronary Artery Disease (FAME 2)

Presenter: Panagiotis Xaplanteris

May 23, 2018

News Conference News EuroPCR 2018

New ORBITA Insights: Invasive Physiology Tests Track Closely With Ischemia, but Not Symptom Improvement

Shelley Wood

May 22, 2018

News Conference News EuroPCR 2018

FFR in PCI for Stable CAD: Lasting Benefit Shown by FAME 2, SCAAR Data

Caitlin E. Cox

May 22, 2018

Presentation EuroPCR 2018

ORBITA: A Physiology-stratified Analysis of the Impact of FFR and iFR on Efficacy of Coronary Angioplasty in Stable Coronary Artery Disease

Presenter: Rasha Al-Lamee

May 22, 2018

News Conference News EuroPCR 2018

FFR-Guided PCI Reduces Risk of Death/MI Compared With Medical Therapy: Pooled Analysis

Michael O'Riordan

May 22, 2018

Advertisement

CTO PCI Improves Total Myocardial Viability, PET Imaging Suggests

FAME 3: PCI Fails to Demonstrate Noninferiority to Surgery in Three-Vessel CAD

New Chest Pain Guidelines Out at Last: Most Tests Have a Role

ORBITA Data Undercut the Idea PCI Does Best in Focal CAD

When PCI Decisions Ignore FFR Results, Patients Pay a Price

Swedish Data ‘Corroborate’ FFR’s Survival Benefit Seen in RCTs

Functionally Significant Nonculprit Lesions Pose Risk in STEMI Patients

Diabetes Does Not Appear to Hinder FFR Insights for CAD

CMR May Help Evaluate Nonculprit Lesions in STEMI Patients

Drug-Coated Balloons in STEMI ‘Safe and Feasible’ in Specific Circumstances: REVELATION

Off to EuroPCR 2019? Expect Mitral and Tricuspid Updates, Thin-Strut Stent Surprises, and ‘Strong’ Statements

FAME 2: 3-Year Clinical and Cost-Effectiveness Outcomes of FFR-Guided PCI in Patients With Coronary Artery Disease

New ESC/EACTS Revascularization Guidelines Make Room for Radial First, STICH, and DES for All

ORBITA Redux: Lancet Correspondence Takes Talk of the Sham-Controlled PCI Trial to Further Heights

Modest Benefit of PCI Over Medical Therapy in Patients With ‘Grey Zone’ FFR Lesions

Five-year Outcomes with PCI Guided by Fractional Flow Reserve in Patients with Stable Coronary Artery Disease (FAME 2)

New ORBITA Insights: Invasive Physiology Tests Track Closely With Ischemia, but Not Symptom Improvement

FFR in PCI for Stable CAD: Lasting Benefit Shown by FAME 2, SCAAR Data

ORBITA: A Physiology-stratified Analysis of the Impact of FFR and iFR on Efficacy of Coronary Angioplasty in Stable Coronary Artery Disease

FFR-Guided PCI Reduces Risk of Death/MI Compared With Medical Therapy: Pooled Analysis

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content